The potential of vortioxetine to improve cognition in schizophrenia is suggested by this brief review. More effective treatments for CIS are needed. It is well established that cognitive impairment is present in virtually all patients with schizophrenia and that it is a limiting factor in social function for these patients, and thus, a major cause of disability and burden on society. Atypical antipsychotic drugs, which share some of the pharmacology of vortioxetine, e.g. 5-HT1A partial agonism and 5-HT7 antagonism, and its effects on neurotransmitter efflux (e.g., enhancing the release of DA, NE, 5-HT, acetylcholine in mPFC) have been shown to improve some domains of cognition in patients with schizophrenia (Woodward et al. 2005). Although there are some who dispute this, this may be due to the data in the CATIE study on cognition which has been invalidated because of failure to consider the impact of tardive dyskinesia on cognition. Our laboratory has pioneered the study of the atypical antipsychotic drugs for cognition clinically and preclinically. Our preclinical studies have utilized subchronic NMDAR receptor antagonist, phencyclidine (PCP), treatment to induce deficits in novel object recognition (NOR) and operant reversal learning (ORL). The subchronic PCP (scPCP) treatment leads to deficits in glutamate and GABA neurotransmission which are consistent with similar deficits in schizophrenia brain.
|Effective start/end date||3/17/16 → 3/17/18|
- Takeda Pharmaceuticals U.S.A., Inc. (Agmt 3/25/16)